Xu Y, Bai R, Zhang Q, Zhang S, Zhang J, Du S
Discov Oncol. 2024; 15(1):220.
PMID: 38858234
PMC: 11164853.
DOI: 10.1007/s12672-024-01083-0.
Oh N, Choi S, Kim S, Lee H, Jang H, Byun J
Eur Radiol. 2023; 34(1):465-474.
PMID: 37532900
DOI: 10.1007/s00330-023-10014-6.
Tabacelia D, Stroescu C, Dumitru R, Grigorescu R, Martiniuc A, Husar-Sburlan I
J Med Life. 2022; 15(1):138-143.
PMID: 35186148
PMC: 8852628.
DOI: 10.25122/jml-2021-0088.
Bezinover D, Geyer N, Dahmus J, Chinchilli V, Stine J
HPB (Oxford). 2021; 24(6):825-832.
PMID: 34772623
PMC: 10691403.
DOI: 10.1016/j.hpb.2021.10.008.
Serenari M, Ravaioli M
Hepatobiliary Surg Nutr. 2020; 9(4):490-492.
PMID: 32832500
PMC: 7423561.
DOI: 10.21037/hbsn.2019.11.10.
Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T, Rasoul-Rockenschaub S, Gyori G, Scheiner B, Trauner M, Soliman T
United European Gastroenterol J. 2020; 9(2):209-219.
PMID: 32741316
PMC: 8259374.
DOI: 10.1177/2050640620948665.
Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function?.
Imai K, Yamashita Y, Nakao Y, Matsumoto T, Kinoshita S, Yusa T
Ann Surg Oncol. 2020; 28(2):854-862.
PMID: 32740735
DOI: 10.1245/s10434-020-08960-2.
Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience.
Ju M, Yopp A
Ann Gastroenterol Surg. 2020; 4(3):208-215.
PMID: 32490334
PMC: 7240148.
DOI: 10.1002/ags3.12316.
C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.
Meischl T, Rasoul-Rockenschaub S, Gyori G, Sieghart W, Reiberger T, Trauner M
PLoS One. 2019; 14(5):e0216677.
PMID: 31141535
PMC: 6541257.
DOI: 10.1371/journal.pone.0216677.
Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?.
Zhang Z, Luo Y, Lu Q, Dai S, Sha W
World J Clin Cases. 2018; 6(9):259-273.
PMID: 30211206
PMC: 6134280.
DOI: 10.12998/wjcc.v6.i9.259.
Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation.
Seo N, Kim M, Park M, Choi J, An C, Han K
Eur Radiol. 2018; 29(2):1022-1031.
PMID: 29974221
DOI: 10.1007/s00330-018-5557-1.
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y, Lee J, Lee D, Cho E, Yu S, Yi N
Oncotarget. 2017; 8(29):47555-47564.
PMID: 28548930
PMC: 5564586.
DOI: 10.18632/oncotarget.17733.
Indications for living donor liver transplantation in patients with hepatocellular carcinoma.
Sugawara Y, Inomata Y
Hepatobiliary Surg Nutr. 2016; 5(5):429-432.
PMID: 27826558
PMC: 5075818.
DOI: 10.21037/hbsn.2016.09.01.
Prognosis for recipients with hepatocellular carcinoma of salvage liver transplantation versus those of primary liver transplantation: a retrospective single-center study.
Wang P, Pu Y, Li H, Shi B, Zheng S, Zhong L
Springerplus. 2016; 5(1):1809.
PMID: 27818858
PMC: 5069219.
DOI: 10.1186/s40064-016-3441-5.
FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.
Lin B, Chen T, Zhang Q, Lu X, Zheng Z, Ding J
Oncotarget. 2016; 7(47):77495-77507.
PMID: 27769048
PMC: 5363599.
DOI: 10.18632/oncotarget.12715.
Is the Hong Kong Liver Cancer staging system the best guide for hepatitis B virus-related hepatocellular carcinoma patients with multiple tumors?.
Liu S, Li X, Li H, Guo L, Zhang B, Zhang J
Oncotarget. 2016; 7(32):51598-51607.
PMID: 27323396
PMC: 5239499.
DOI: 10.18632/oncotarget.9956.
Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria.
Gunay Y, Guler N, Yaprak O, Dayangac M, Akyildiz M, Altaca G
Indian J Surg. 2016; 77(Suppl 3):950-6.
PMID: 27011489
PMC: 4775624.
DOI: 10.1007/s12262-014-1078-6.
Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience.
Wang P, Wang C, Li H, Shi B, Wang J, Zhong L
Onco Targets Ther. 2016; 8:3775-81.
PMID: 26719705
PMC: 4689267.
DOI: 10.2147/OTT.S93939.
Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.
Park H, Jang K, Kang T, Song K, Kim S, Kim Y
Eur Radiol. 2015; 26(9):3102-11.
PMID: 26634931
DOI: 10.1007/s00330-015-4136-y.
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.
Kumar A, Acharya S, Singh S, Saraswat V, Arora A, Duseja A
J Clin Exp Hepatol. 2015; 4(Suppl 3):S3-S26.
PMID: 25755608
PMC: 4284289.
DOI: 10.1016/j.jceh.2014.04.003.
